In addition to the great answers and interesting publications from Dr.Mallem and Dr.Aldallal, I would recommend the following publication from Dr.Phillips, an experienced pharmacologist with successful developments in the field of asthma:
Phillips et al. - Predicting drug efficacy using integrative models for chronic respiratory diseases.
http://www.ncbi.nlm.nih.gov/pubmed/23517645
Dr.Phillips encourages the use of physiological and clinically-relevant outcomes such as resistance, compliance, FEV and tissue mechanics. These endpoints go beyond traditional biomarkers, and provide unique insights into the respiratory system.
Such outcomes can easily be measured with the flexiVent, even for researchers with little or no physiology background. The flexiVent is an integrated ventilator and lung function measurement platform for in vivo research. (Disclosure: I work for SCIREQ, the manufacturer of the flexiVent)
Please find below a video from the Journal of Visual Experiments (JOVE) showing how a typical experiment is carried out with the flexiVent:
You will also find additional information on how our to create reproducible AHR disease models (OVA, HDM, etc.) or other sensitisation protocols, screen your compounds in conscious, freely moving subject, and take detailed measurements of airway hyperreactivity to assess the efficacy of your compounds:
http://www.scireq.com/applications/asthma
If you need additional help or information, please feel free to contact us directly. We also have offices in India, and our applications specialists and scientists will be happy to further assist you in your research.